Loading…

A population‐based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy

Study Type – Therapy (cohort) Level of Evidence  2b What's known on the subject? and What does the study add? The National Comprehensive Cancer Network guidelines recommend pelvic lymph node dissection in patients with a nomogram‐predicted lymph node invasion risk of 2% or more. We set out to e...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2012-04, Vol.109 (8), p.1177-1182
Main Authors: Abdollah, Firas, Schmitges, Jan, Sun, Maxine, Shariat, Shahrokh F., Briganti, Alberto, Abdo, Al'a, Tian, Zhe, Perrotte, Paul, Montorsi, Francesco, Karakiewicz, Pierre I.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4278-510f09f2c6d06bc3ab5c65b9448ed216327d456e34a7ad9afecd52d54f04ac503
cites cdi_FETCH-LOGICAL-c4278-510f09f2c6d06bc3ab5c65b9448ed216327d456e34a7ad9afecd52d54f04ac503
container_end_page 1182
container_issue 8
container_start_page 1177
container_title BJU international
container_volume 109
creator Abdollah, Firas
Schmitges, Jan
Sun, Maxine
Shariat, Shahrokh F.
Briganti, Alberto
Abdo, Al'a
Tian, Zhe
Perrotte, Paul
Montorsi, Francesco
Karakiewicz, Pierre I.
description Study Type – Therapy (cohort) Level of Evidence  2b What's known on the subject? and What does the study add? The National Comprehensive Cancer Network guidelines recommend pelvic lymph node dissection in patients with a nomogram‐predicted lymph node invasion risk of 2% or more. We set out to examine the validity of this recommendation. OBJECTIVES •  To examine the ability of the threshold recommended by the National Comprehensive Cancer Network (NCCN) in correctly predicting histologically‐confirmed lymph node invasion (LNI). •  The 2010 NCCN practice guidelines for prostate cancer recommend a pelvic lymph node dissection (PLND) at radical prostatectomy in all individuals with a nomogram predicted LNI risk of ≥2%. PATIENTS AND METHODS •  We assessed 20 877 patients who were treated with radical prostatectomy and PLND between 2004 and 2006, within the Surveillance, Epidemiology and End Results database. •  The 2% nomogram threshold, as well as other threshold values (range 1–10%) were tested. •  Finally, we externally validated the NCCN guideline nomogram. RESULTS •  Overall, 2.5% of patients had LNI. •  The use of the 2% threshold would allow the avoidance of 23% of PLNDs, at the cost of missing 1.7% of patients with LNI. Conversely, the use of a 3% threshold would allow the avoidance of 58% of PLNDs, at the cost of missing 15% of patients with LNI vs 72% and 26%, respectively, for the 4% threshold. •  Overall, the accuracy of the NCCN guideline nomogram quantified according to the receiver‐operator characteristics‐derived area under the curve was 82%. CONCLUSIONS •  In a population‐based sample, the NCCN guideline nomogram is highly accurate. •  However, the 2% threshold will permit the avoidance of only 23% of PLNDs, instead of the 48% intended by the NCCN guidelines. •  The use of a 3% threshold may allow a lower rate of PLND overtreatment, although it will miss more patients with LNI.
doi_str_mv 10.1111/j.1464-410X.2011.10518.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_963490692</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2975487891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4278-510f09f2c6d06bc3ab5c65b9448ed216327d456e34a7ad9afecd52d54f04ac503</originalsourceid><addsrcrecordid>eNqNkUuO1DAQhiMEYh5wBWQJIVYd_O5kgzS0eGo0bBiJneW2K7QbJw52MjO9myNwCS7GSXDSPYPECm9ccn1_lav-okAElySfV9uScMkXnOCvJcWElAQLUpU3D4rj-8TDuxjX8qg4SWmLcX6Q4nFxRElV4aw5Ln6doT70o9eDC93v259rncAinRKk1EI3oNCgYQPoYga0R6vQ9hE20CV3BWilOwMRXcBwHeJ31EdtBmcAfRudBe86QK6zzszihJoQUQ_-yhnkd22_QV2wgKzL3cxEID2gqCfe51IhDXrIidDunhSPGu0TPD3cp8Xlu7dfVh8W55_ff1ydnS8Mp8tqIQhucN1QIy2Wa8P0Whgp1jXnFVhKJKNLy4UExvVS21o3YKygVvAGc20EZqfFy33d3P3HCGlQrUsGvNcdhDGpWjJeY1nTTD7_h9yGMeYFJUWYYExSOlPVnjJ5mhShUX10rY47RbCanFRbNZmkJsPU5KSanVQ3Wfrs0GBct2DvhXfWZeDFAdApL6yJ2QqX_nJiWTFBp5le77lr52H33x9Qbz5dziH7A9ItvrE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1353362292</pqid></control><display><type>article</type><title>A population‐based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Abdollah, Firas ; Schmitges, Jan ; Sun, Maxine ; Shariat, Shahrokh F. ; Briganti, Alberto ; Abdo, Al'a ; Tian, Zhe ; Perrotte, Paul ; Montorsi, Francesco ; Karakiewicz, Pierre I.</creator><creatorcontrib>Abdollah, Firas ; Schmitges, Jan ; Sun, Maxine ; Shariat, Shahrokh F. ; Briganti, Alberto ; Abdo, Al'a ; Tian, Zhe ; Perrotte, Paul ; Montorsi, Francesco ; Karakiewicz, Pierre I.</creatorcontrib><description>Study Type – Therapy (cohort) Level of Evidence  2b What's known on the subject? and What does the study add? The National Comprehensive Cancer Network guidelines recommend pelvic lymph node dissection in patients with a nomogram‐predicted lymph node invasion risk of 2% or more. We set out to examine the validity of this recommendation. OBJECTIVES •  To examine the ability of the threshold recommended by the National Comprehensive Cancer Network (NCCN) in correctly predicting histologically‐confirmed lymph node invasion (LNI). •  The 2010 NCCN practice guidelines for prostate cancer recommend a pelvic lymph node dissection (PLND) at radical prostatectomy in all individuals with a nomogram predicted LNI risk of ≥2%. PATIENTS AND METHODS •  We assessed 20 877 patients who were treated with radical prostatectomy and PLND between 2004 and 2006, within the Surveillance, Epidemiology and End Results database. •  The 2% nomogram threshold, as well as other threshold values (range 1–10%) were tested. •  Finally, we externally validated the NCCN guideline nomogram. RESULTS •  Overall, 2.5% of patients had LNI. •  The use of the 2% threshold would allow the avoidance of 23% of PLNDs, at the cost of missing 1.7% of patients with LNI. Conversely, the use of a 3% threshold would allow the avoidance of 58% of PLNDs, at the cost of missing 15% of patients with LNI vs 72% and 26%, respectively, for the 4% threshold. •  Overall, the accuracy of the NCCN guideline nomogram quantified according to the receiver‐operator characteristics‐derived area under the curve was 82%. CONCLUSIONS •  In a population‐based sample, the NCCN guideline nomogram is highly accurate. •  However, the 2% threshold will permit the avoidance of only 23% of PLNDs, instead of the 48% intended by the NCCN guidelines. •  The use of a 3% threshold may allow a lower rate of PLND overtreatment, although it will miss more patients with LNI.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2011.10518.x</identifier><identifier>PMID: 21880105</identifier><identifier>CODEN: BJINFO</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adenocarcinoma - epidemiology ; Adenocarcinoma - secondary ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biopsy ; Dissection ; Follow-Up Studies ; Guideline Adherence ; Hematologic and hematopoietic diseases ; Humans ; Incidence ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymph Node Excision - methods ; lymph node excision/statistics and numerical data ; Lymph Nodes - pathology ; Lymph Nodes - surgery ; Lymphatic Metastasis ; lymphatic metastasis/diagnosis ; Lymphatic system ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Pelvis ; Prostatectomy - methods ; prostatic neoplasm/pathology ; Prostatic Neoplasms - epidemiology ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Retrospective Studies ; Risk Assessment - methods ; SEER Program ; Survival Rate - trends ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>BJU international, 2012-04, Vol.109 (8), p.1177-1182</ispartof><rights>2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL</rights><rights>2015 INIST-CNRS</rights><rights>2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4278-510f09f2c6d06bc3ab5c65b9448ed216327d456e34a7ad9afecd52d54f04ac503</citedby><cites>FETCH-LOGICAL-c4278-510f09f2c6d06bc3ab5c65b9448ed216327d456e34a7ad9afecd52d54f04ac503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25783520$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21880105$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdollah, Firas</creatorcontrib><creatorcontrib>Schmitges, Jan</creatorcontrib><creatorcontrib>Sun, Maxine</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>Abdo, Al'a</creatorcontrib><creatorcontrib>Tian, Zhe</creatorcontrib><creatorcontrib>Perrotte, Paul</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I.</creatorcontrib><title>A population‐based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Study Type – Therapy (cohort) Level of Evidence  2b What's known on the subject? and What does the study add? The National Comprehensive Cancer Network guidelines recommend pelvic lymph node dissection in patients with a nomogram‐predicted lymph node invasion risk of 2% or more. We set out to examine the validity of this recommendation. OBJECTIVES •  To examine the ability of the threshold recommended by the National Comprehensive Cancer Network (NCCN) in correctly predicting histologically‐confirmed lymph node invasion (LNI). •  The 2010 NCCN practice guidelines for prostate cancer recommend a pelvic lymph node dissection (PLND) at radical prostatectomy in all individuals with a nomogram predicted LNI risk of ≥2%. PATIENTS AND METHODS •  We assessed 20 877 patients who were treated with radical prostatectomy and PLND between 2004 and 2006, within the Surveillance, Epidemiology and End Results database. •  The 2% nomogram threshold, as well as other threshold values (range 1–10%) were tested. •  Finally, we externally validated the NCCN guideline nomogram. RESULTS •  Overall, 2.5% of patients had LNI. •  The use of the 2% threshold would allow the avoidance of 23% of PLNDs, at the cost of missing 1.7% of patients with LNI. Conversely, the use of a 3% threshold would allow the avoidance of 58% of PLNDs, at the cost of missing 15% of patients with LNI vs 72% and 26%, respectively, for the 4% threshold. •  Overall, the accuracy of the NCCN guideline nomogram quantified according to the receiver‐operator characteristics‐derived area under the curve was 82%. CONCLUSIONS •  In a population‐based sample, the NCCN guideline nomogram is highly accurate. •  However, the 2% threshold will permit the avoidance of only 23% of PLNDs, instead of the 48% intended by the NCCN guidelines. •  The use of a 3% threshold may allow a lower rate of PLND overtreatment, although it will miss more patients with LNI.</description><subject>Adenocarcinoma - epidemiology</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Dissection</subject><subject>Follow-Up Studies</subject><subject>Guideline Adherence</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Incidence</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymph Node Excision - methods</subject><subject>lymph node excision/statistics and numerical data</subject><subject>Lymph Nodes - pathology</subject><subject>Lymph Nodes - surgery</subject><subject>Lymphatic Metastasis</subject><subject>lymphatic metastasis/diagnosis</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Pelvis</subject><subject>Prostatectomy - methods</subject><subject>prostatic neoplasm/pathology</subject><subject>Prostatic Neoplasms - epidemiology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Retrospective Studies</subject><subject>Risk Assessment - methods</subject><subject>SEER Program</subject><subject>Survival Rate - trends</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkUuO1DAQhiMEYh5wBWQJIVYd_O5kgzS0eGo0bBiJneW2K7QbJw52MjO9myNwCS7GSXDSPYPECm9ccn1_lav-okAElySfV9uScMkXnOCvJcWElAQLUpU3D4rj-8TDuxjX8qg4SWmLcX6Q4nFxRElV4aw5Ln6doT70o9eDC93v259rncAinRKk1EI3oNCgYQPoYga0R6vQ9hE20CV3BWilOwMRXcBwHeJ31EdtBmcAfRudBe86QK6zzszihJoQUQ_-yhnkd22_QV2wgKzL3cxEID2gqCfe51IhDXrIidDunhSPGu0TPD3cp8Xlu7dfVh8W55_ff1ydnS8Mp8tqIQhucN1QIy2Wa8P0Whgp1jXnFVhKJKNLy4UExvVS21o3YKygVvAGc20EZqfFy33d3P3HCGlQrUsGvNcdhDGpWjJeY1nTTD7_h9yGMeYFJUWYYExSOlPVnjJ5mhShUX10rY47RbCanFRbNZmkJsPU5KSanVQ3Wfrs0GBct2DvhXfWZeDFAdApL6yJ2QqX_nJiWTFBp5le77lr52H33x9Qbz5dziH7A9ItvrE</recordid><startdate>201204</startdate><enddate>201204</enddate><creator>Abdollah, Firas</creator><creator>Schmitges, Jan</creator><creator>Sun, Maxine</creator><creator>Shariat, Shahrokh F.</creator><creator>Briganti, Alberto</creator><creator>Abdo, Al'a</creator><creator>Tian, Zhe</creator><creator>Perrotte, Paul</creator><creator>Montorsi, Francesco</creator><creator>Karakiewicz, Pierre I.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>201204</creationdate><title>A population‐based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy</title><author>Abdollah, Firas ; Schmitges, Jan ; Sun, Maxine ; Shariat, Shahrokh F. ; Briganti, Alberto ; Abdo, Al'a ; Tian, Zhe ; Perrotte, Paul ; Montorsi, Francesco ; Karakiewicz, Pierre I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4278-510f09f2c6d06bc3ab5c65b9448ed216327d456e34a7ad9afecd52d54f04ac503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma - epidemiology</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Dissection</topic><topic>Follow-Up Studies</topic><topic>Guideline Adherence</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Incidence</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymph Node Excision - methods</topic><topic>lymph node excision/statistics and numerical data</topic><topic>Lymph Nodes - pathology</topic><topic>Lymph Nodes - surgery</topic><topic>Lymphatic Metastasis</topic><topic>lymphatic metastasis/diagnosis</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Pelvis</topic><topic>Prostatectomy - methods</topic><topic>prostatic neoplasm/pathology</topic><topic>Prostatic Neoplasms - epidemiology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Retrospective Studies</topic><topic>Risk Assessment - methods</topic><topic>SEER Program</topic><topic>Survival Rate - trends</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdollah, Firas</creatorcontrib><creatorcontrib>Schmitges, Jan</creatorcontrib><creatorcontrib>Sun, Maxine</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>Abdo, Al'a</creatorcontrib><creatorcontrib>Tian, Zhe</creatorcontrib><creatorcontrib>Perrotte, Paul</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Karakiewicz, Pierre I.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdollah, Firas</au><au>Schmitges, Jan</au><au>Sun, Maxine</au><au>Shariat, Shahrokh F.</au><au>Briganti, Alberto</au><au>Abdo, Al'a</au><au>Tian, Zhe</au><au>Perrotte, Paul</au><au>Montorsi, Francesco</au><au>Karakiewicz, Pierre I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A population‐based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2012-04</date><risdate>2012</risdate><volume>109</volume><issue>8</issue><spage>1177</spage><epage>1182</epage><pages>1177-1182</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><coden>BJINFO</coden><abstract>Study Type – Therapy (cohort) Level of Evidence  2b What's known on the subject? and What does the study add? The National Comprehensive Cancer Network guidelines recommend pelvic lymph node dissection in patients with a nomogram‐predicted lymph node invasion risk of 2% or more. We set out to examine the validity of this recommendation. OBJECTIVES •  To examine the ability of the threshold recommended by the National Comprehensive Cancer Network (NCCN) in correctly predicting histologically‐confirmed lymph node invasion (LNI). •  The 2010 NCCN practice guidelines for prostate cancer recommend a pelvic lymph node dissection (PLND) at radical prostatectomy in all individuals with a nomogram predicted LNI risk of ≥2%. PATIENTS AND METHODS •  We assessed 20 877 patients who were treated with radical prostatectomy and PLND between 2004 and 2006, within the Surveillance, Epidemiology and End Results database. •  The 2% nomogram threshold, as well as other threshold values (range 1–10%) were tested. •  Finally, we externally validated the NCCN guideline nomogram. RESULTS •  Overall, 2.5% of patients had LNI. •  The use of the 2% threshold would allow the avoidance of 23% of PLNDs, at the cost of missing 1.7% of patients with LNI. Conversely, the use of a 3% threshold would allow the avoidance of 58% of PLNDs, at the cost of missing 15% of patients with LNI vs 72% and 26%, respectively, for the 4% threshold. •  Overall, the accuracy of the NCCN guideline nomogram quantified according to the receiver‐operator characteristics‐derived area under the curve was 82%. CONCLUSIONS •  In a population‐based sample, the NCCN guideline nomogram is highly accurate. •  However, the 2% threshold will permit the avoidance of only 23% of PLNDs, instead of the 48% intended by the NCCN guidelines. •  The use of a 3% threshold may allow a lower rate of PLND overtreatment, although it will miss more patients with LNI.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21880105</pmid><doi>10.1111/j.1464-410X.2011.10518.x</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1464-4096
ispartof BJU international, 2012-04, Vol.109 (8), p.1177-1182
issn 1464-4096
1464-410X
language eng
recordid cdi_proquest_miscellaneous_963490692
source Wiley-Blackwell Read & Publish Collection
subjects Adenocarcinoma - epidemiology
Adenocarcinoma - secondary
Adenocarcinoma - surgery
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biopsy
Dissection
Follow-Up Studies
Guideline Adherence
Hematologic and hematopoietic diseases
Humans
Incidence
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymph Node Excision - methods
lymph node excision/statistics and numerical data
Lymph Nodes - pathology
Lymph Nodes - surgery
Lymphatic Metastasis
lymphatic metastasis/diagnosis
Lymphatic system
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Pelvis
Prostatectomy - methods
prostatic neoplasm/pathology
Prostatic Neoplasms - epidemiology
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
Retrospective Studies
Risk Assessment - methods
SEER Program
Survival Rate - trends
Tumors of the urinary system
Urinary tract. Prostate gland
title A population‐based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T06%3A11%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20population%E2%80%90based%20assessment%20of%20the%20National%20Comprehensive%20Cancer%20Network%20practice%20guideline%20indications%20for%20pelvic%20lymph%20node%20dissection%20at%20radical%20prostatectomy&rft.jtitle=BJU%20international&rft.au=Abdollah,%20Firas&rft.date=2012-04&rft.volume=109&rft.issue=8&rft.spage=1177&rft.epage=1182&rft.pages=1177-1182&rft.issn=1464-4096&rft.eissn=1464-410X&rft.coden=BJINFO&rft_id=info:doi/10.1111/j.1464-410X.2011.10518.x&rft_dat=%3Cproquest_cross%3E2975487891%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4278-510f09f2c6d06bc3ab5c65b9448ed216327d456e34a7ad9afecd52d54f04ac503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1353362292&rft_id=info:pmid/21880105&rfr_iscdi=true